Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy

ClinicalTrials.gov ID: NCT00431067

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00431067. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this trial is to explore the efficacy of BIBW 2992 in HER2 positive metastatic breast cancer patients after failure of trastuzumab containing regimens.

Study identification

NCT ID: NCT00431067
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Boehringer Ingelheim; Industry
Enrollment: 41 participants

Conditions and interventions

Conditions

Breast Neoplasms

Interventions

BIBW 2992 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 2006 (Type not available)
Primary completion: Aug 2009 (Actual)
Completion: Not listed
Last update posted: Jun 9, 2014

Started 2006

United States locations

U.S. sites: 6
U.S. states: 5
U.S. cities: 6

Facility	City	State	ZIP	Site status
1200.11.3 Boehringer Ingelheim Investigational Site	Scottsdale	Arizona	—	—
1200.11.7 Boehringer Ingelheim Investigational Site	Encinitas	California	—	—
1200.11.4 Boehringer Ingelheim Investigational Site	Santa Monica	California	—	—
1200.11.2 Boehringer Ingelheim Investigational Site	Tampa	Florida	—	—
1200.11.1 Boehringer Ingelheim Investigational Site	Boston	Massachusetts	—	—
1200.11.5 Boehringer Ingelheim Investigational Site	Chapel Hill	North Carolina	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00431067, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 9, 2014 · Synced Nov 14, 2026